🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT06709144
Active, not recruiting Phase 3

Borderline of CME/D3 Dissection for Local Advanced Right-sided Colon Cancer

NCT06709144 · tracked via the Priya Life Science China tracker
Sponsor
Haixing Ju, MD
Phase
Phase 3
Started
2024-07-01
Last updated
2024-11-29

Condition(s) studied

Colon Cancer

Investigational drug(s) / intervention(s)

SMA lymph node dissectionSMV lymph node dissection

SMA lymph node dissection: The lymph node dissection boundary is on the left side of the superior mesenteric artery (SMA)

SMV lymph node dissection: The lymph node dissection boundary is on the left side of the superior mesenteric vein (SMV)

Study summary

The study was conducted on patients with advanced right-sided colon cancer, and the clinical pathological and prognostic data of the patients were compared between the two groups of patients who were randomly divided into those undergoing SMV and SMA left resection, with the aim of resolving the controversy over the left resection boundary of CME/D3 lymph node dissection through this study, and to clarify whether SMA left resection is superior to SMV left resection.

Eligibility

Sex
ALL
Min age
18 Years
Max age
78 Years
Healthy volunteers
No
Inclusion Criteria: * right side colon cancer(The primary lesion is located in the ileocecal region, ascending colon, hepatic flexure of colon, or proximal transverse colon) * T3-4 and/or N1-2M0 * Colonoscopy and pathological biopsy confirmed colon adenocarcinoma Exclusion Criteria: * T1-2N0M0 * Cannot undergo curative resection * Simultaneous multiple primary colorectal cancer or other diseases requiring segmental resection * Distant metastasis * Tumor invades surrounding organs, requiring joint organ resection * Emergency surgery is required for complications such as intestinal obstruction, perforation, and bleeding * Patients who have received neoadjuvant therapy before surgery * Pregnant or lactating women * Patients who are not suitable or unable to tolerate surgery

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Zhejiang cancer hospital Hangzhou Zhejiang

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06709144 on ClinicalTrials.gov ↗ ← All trials in China